A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02).

Shamir N KalariaMichael ArmahizerPaul McCarthyNeeraj BadjatiaJogarao V S GobburuMathangi Gopalakrishnan

Published in: British journal of clinical pharmacology (2021)

CVVH clearance contributed a major fraction of the total lacosamide clearance in neurocritically ill patients. Given that drug clearance increases with higher effluent flow rates, lacosamide dosing regimens should be increased to match exposures observed in patients with normal renal function.

Keyphrases

patients undergoing
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
extracorporeal membrane oxygenation
wastewater treatment
prognostic factors
emergency department